This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hutchinson, D.B.A. Articles by Farquhar, J.A. Search for Related Content PubMed Articles by Hutchinson, D.B.A. Articles by Farquhar, J.A. Social Bookmarking                   What's this?

Agranulocytosis Associated with Maloprim: Review of Cases

Clinical and Applied Research Division, Wellcome Research Laboratories, Beckenham, Kent, UK

P.D. Whiteman

Clinical and Applied Research Division, Wellcome Research Laboratories, Beckenham, Kent, UK

J.A. Farquhar

Clinical Immunology and Chemotherapy Department, Building 10, Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, UK

1 Twenty-one cases of agranulocytosis following dosage with one tablet of Maloprim given once or twice weekly are reviewed.

2 Of the 18 individuals for whom the dose is certain 12 were taking twice-weekly Maloprim. Time of onset was 7-9 weeks in 15 of 19 cases where duration of dosage is known.

3 Nine patients died, 12 recovered. Of those who died six were taking Maloprim twice weekly, one once weekly and two at an uncertain dosage.

4 The available data suggest that this is an idiosyncratic reaction to dapsone exacerbated by the concomitant administration of pyrimethamine.

Human & Experimental Toxicology, Vol. 5, No. 4, 221-227 (1986)
DOI: 10.1177/096032718600500402


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?